Drug Manufacturing and Formulation Program (DMFP)

IDIQ

Description

Conduct studies that will support the development and manufacture of dosage forms of small molecule drug candidates suitable for administration in preclinical and clinical studies of neurological disease/disorders. Services to be provided include: manufacture the
active pharmaceutical ingredient (API), formulate the API, package, label, store, and distribute completed drug product.

Overview

Ceiling

None

Primary Sponsoring Agency

National Institute on Drug Abuse (NIDA) [HHS - NIH]

Who Can Use

One Agency

Primary NAICS

325412 - Pharmaceutical Preparation Manufacturing

Primary PSC

AZ13 - R&D- Other Research And Development (Advanced Development)

Primary Set Aside

None

Extent Competed

Full And Open Competition

Related Opportunity

Drug Manufacturing and Formulation Program (DMFP) (NIH-NINDS-14-02)

Drug Manufacturing and Formulation Program (DMFP) awarded by National Institute on Drug Abuse (NIDA) in January 2015 accepts orders through January 2025. The IDIQ has no ceiling, and as of today, $21,744,616 has been obligated through the vehicle with a total reported backlog of $7,938,425. The IDIQ was awarded full & open and has a primary NAICS code of 325412.

Award Hierarchy

Vehicle

Drug Manufacturing and Formulation Program (DMFP)

Indefinite Delivery Vehicles

Prime Contracts

Subcontracts

Status

Period of Performance

1/15/15

Start Date

1/14/25

Ordering Period End Date

100% Complete

Task Order Obligations and Backlog

$21.7M

Total Obligated

$21.7M

Current Award

$29.7M

Potential Award

73% Funded

$0.0

Funded Backlog

$7.9M

Total Backlog

Vehicle Award Share

Contractors with greatest percentage of obligations for Drug Manufacturing and Formulation Program (DMFP)

Vehicle Award Share

Federal Award Analysis